IN2014MN01442A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01442A IN2014MN01442A IN1442MUN2014A IN2014MN01442A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A IN 1442MUN2014 A IN1442MUN2014 A IN 1442MUN2014A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- diabetes
- type
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012007840 | 2012-01-18 | ||
| PCT/JP2013/050710 WO2013108800A1 (fr) | 2012-01-18 | 2013-01-17 | Dérivé de phénylazole substitué |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01442A true IN2014MN01442A (fr) | 2015-07-03 |
Family
ID=48799224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1442MUN2014 IN2014MN01442A (fr) | 2012-01-18 | 2013-01-17 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9233958B2 (fr) |
| EP (2) | EP3009433B1 (fr) |
| JP (2) | JP6104181B2 (fr) |
| KR (1) | KR20140113688A (fr) |
| CN (1) | CN104159892A (fr) |
| AU (1) | AU2013210394A1 (fr) |
| BR (1) | BR112014017656A2 (fr) |
| CA (1) | CA2861847A1 (fr) |
| CO (1) | CO7020920A2 (fr) |
| ES (2) | ES2640667T3 (fr) |
| HK (2) | HK1200824A1 (fr) |
| IL (1) | IL233682A0 (fr) |
| IN (1) | IN2014MN01442A (fr) |
| MX (1) | MX2014008790A (fr) |
| NZ (1) | NZ627303A (fr) |
| PH (1) | PH12014501646A1 (fr) |
| RU (1) | RU2014133738A (fr) |
| SG (1) | SG11201404026SA (fr) |
| TW (1) | TWI551590B (fr) |
| WO (1) | WO2013108800A1 (fr) |
| ZA (1) | ZA201405108B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2640667T3 (es) | 2012-01-18 | 2017-11-03 | Daiichi Sankyo Company, Limited | Derivados de 2-fenil-1,3-oxazol y 5-fenil-1,2,4-oxadiazol para el tratamiento de diabetes |
| JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
| WO2017104782A1 (fr) * | 2015-12-17 | 2017-06-22 | 第一三共株式会社 | Procédé de préparation d'un composé d'oxadiazole |
| EP3766879A1 (fr) * | 2019-07-19 | 2021-01-20 | Basf Se | Dérivés de pytazole pesticides |
| CN111388471B (zh) * | 2020-03-03 | 2021-01-12 | 牡丹江医学院 | 一种治疗胆囊炎的药物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
| NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
| CN1997633A (zh) * | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的三唑及其制备方法 |
| KR20080027908A (ko) | 2005-06-30 | 2008-03-28 | 프로시디온 리미티드 | Ｇｐｃｒ 효능제 |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| BRPI0616457A2 (pt) * | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de fenil-1,2 oxadiazolona com grupo fenila, bem como seu uso, composição farmacêutica compreendendo os mesmos e seu processo de preparação |
| MX2008012814A (es) * | 2006-04-06 | 2008-10-17 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g heterociclicos. |
| GB0606913D0 (en) * | 2006-04-06 | 2006-05-17 | Prosidion Ltd | Compounds |
| KR20100033419A (ko) * | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체 |
| MX2010004232A (es) | 2007-10-16 | 2010-09-30 | Daiichi Sankyo Co Ltd | Compuesto de indolina de pirimidilo. |
| EP2241558A1 (fr) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Dérivés d'oxadiazole |
| WO2010119881A1 (fr) | 2009-04-15 | 2010-10-21 | 第一三共株式会社 | Composé d'indoline |
| EP2468737B1 (fr) * | 2009-08-05 | 2013-10-30 | Daiichi Sankyo Company, Limited | Dérivé de sulfone |
| KR20120051670A (ko) * | 2009-08-05 | 2012-05-22 | 다이이찌 산쿄 가부시키가이샤 | 아미드 유도체 |
| CA2814628C (fr) * | 2010-10-14 | 2015-06-16 | Daiichi Sankyo Company, Limited | Derive d'acylbenzene |
| AU2012291150A1 (en) | 2011-07-29 | 2014-02-20 | Daiichi Sankyo Company, Limited | N-hetero-ring-substituted amide derivative |
| ES2640667T3 (es) | 2012-01-18 | 2017-11-03 | Daiichi Sankyo Company, Limited | Derivados de 2-fenil-1,3-oxazol y 5-fenil-1,2,4-oxadiazol para el tratamiento de diabetes |
-
2013
- 2013-01-17 ES ES15192148.3T patent/ES2640667T3/es active Active
- 2013-01-17 CA CA2861847A patent/CA2861847A1/fr not_active Abandoned
- 2013-01-17 AU AU2013210394A patent/AU2013210394A1/en not_active Abandoned
- 2013-01-17 WO PCT/JP2013/050710 patent/WO2013108800A1/fr active IP Right Grant
- 2013-01-17 HK HK15101292.6A patent/HK1200824A1/en unknown
- 2013-01-17 MX MX2014008790A patent/MX2014008790A/es unknown
- 2013-01-17 IN IN1442MUN2014 patent/IN2014MN01442A/en unknown
- 2013-01-17 NZ NZ627303A patent/NZ627303A/en not_active IP Right Cessation
- 2013-01-17 JP JP2013554315A patent/JP6104181B2/ja not_active Expired - Fee Related
- 2013-01-17 KR KR1020147019737A patent/KR20140113688A/ko not_active Withdrawn
- 2013-01-17 EP EP15192148.3A patent/EP3009433B1/fr not_active Not-in-force
- 2013-01-17 US US14/372,832 patent/US9233958B2/en not_active Expired - Fee Related
- 2013-01-17 ES ES13738825.2T patent/ES2602962T3/es active Active
- 2013-01-17 BR BR112014017656A patent/BR112014017656A2/pt not_active IP Right Cessation
- 2013-01-17 SG SG11201404026SA patent/SG11201404026SA/en unknown
- 2013-01-17 TW TW102101765A patent/TWI551590B/zh not_active IP Right Cessation
- 2013-01-17 EP EP13738825.2A patent/EP2805941B1/fr not_active Not-in-force
- 2013-01-17 CN CN201380014867.6A patent/CN104159892A/zh active Pending
- 2013-01-17 RU RU2014133738A patent/RU2014133738A/ru not_active Application Discontinuation
-
2014
- 2014-07-11 ZA ZA2014/05108A patent/ZA201405108B/en unknown
- 2014-07-17 PH PH12014501646A patent/PH12014501646A1/en unknown
- 2014-07-17 IL IL233682A patent/IL233682A0/en unknown
- 2014-07-31 CO CO14166876A patent/CO7020920A2/es unknown
-
2015
- 2015-02-05 HK HK16108406.3A patent/HK1220448A1/en unknown
- 2015-12-01 US US14/956,116 patent/US20160081993A1/en not_active Abandoned
- 2015-12-01 US US14/956,240 patent/US9725438B2/en not_active Expired - Fee Related
-
2016
- 2016-12-20 JP JP2016247095A patent/JP2017052800A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706719B (en) | Pirfenidone treatment for patients with atypical liver function | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| MY189483A (en) | Purinone derivative | |
| MX348564B (es) | Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos. | |
| WO2013019561A8 (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| WO2012117000A8 (fr) | 3-aminopyridines en tant qu'agonistes de gpbar1 | |
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| IN2014MN01442A (fr) | ||
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| WO2013155528A3 (fr) | Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides | |
| PH12014502802A1 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| IN2014DN05972A (fr) | ||
| CY1116303T1 (el) | Παραγωγο ακυλβενζολιου | |
| AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
| MX2012001107A (es) | Derivado de amida. | |
| PH12014500251A1 (en) | N-hetero-ring-substituted amide derivative | |
| MX2012012410A (es) | Agente terapeutico y agente preventivo para enfermedad de alzheimer. | |
| WO2012091425A3 (fr) | Composition contenant, comme principe actif, un analogue de 4-hydroxytamoxifène ou un sel pharmaceutiquement acceptable de celui-ci, destinée à la prévention ou au traitement des maladies associées au syndrome métabolique | |
| CA2863110A1 (fr) | Derives de 1,2-pyridazine, 1,6-pyridazine ou pyrimidine-benzamide comme modulateurs de gpbar1 | |
| WO2011026193A8 (fr) | Composés cytotoxiques | |
| HK1192725A1 (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients | |
| UA52171U (ru) | Способ лечения дезадаптации сердечно-сосудистой системы у новорожденных с синдромом аспирации мекония | |
| NZ600486A (en) | Pirfenidone treatment for patients with atypical liver function | |
| TH153171A (th) | อนุพันธ์เฟนิแลโซลซึ่งถูกแทนที่ |